Cover Image


Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts

出版商 Amadee & Company, Inc. 商品編碼 301230
出版日期 內容資訊 英文 299 pages
Back to Top
抗生素及新超級藥物的探求:技術、市場、競爭企業、機會分析與預測 Antibiotics And The Quest For New Super Drugs:Technologies, Markets, Competitors And Opportunities-2017-2022 Analysis And Forecasts
出版日期: 2017年07月11日 內容資訊: 英文 299 pages





  • 菌的分類
  • 病原菌的背景
  • 抗生素定義
  • 超級藥物的探求
  • 土壤微生物
  • 抗生素的分類
  • 克陽性 vs. 革蘭氏陰性菌
  • 敏銳度,有效性,及MIC
  • 殺菌性抗生素
  • 功效及安全性、其他

ESKAPE (腸球菌、黃色葡萄球菌、克雷伯菌、鮑曼不動桿菌、綠膿桿菌、腸桿菌)

  • 最常見的感染疾病
  • 抗生素抗性的預防
  • 國家行動計劃對抗抗生素抗性菌
  • BARDA 及 NIAID 預算
  • 國家科學技術諮詢會議 (韓國)
  • 英國的抗微生物藥抗性相關檢討
  • Margolis Center for Health Policy (美國)
  • GAIN Act (美國)
  • 21st Century Cures Act (美國)
  • MRSA的減少、其他


  • 發現平台的崩壞
  • 新的抗生素發現流程
  • 現有抗生素的合理性改善
  • 舊抗生素的再發現
  • 以不同目的再利用舊的醫藥品
  • 發現未實驗的新化學物質的多樣性
  • 目標為基礎的方法
  • 長期性的低成功率
  • 以新抗菌藥的確立為焦點
  • 新抗菌藥類級的不足、其他


  • 抗生素的生產規模 (以金額為準)
  • 生產規模:各級 (以金額為準)
  • 奎諾酮類抗生素(Quinolones)類
  • 頭孢菌素
  • 大環內酯類
  • 青霉素
  • 碳青霉烯類
  • Tetracyclines
  • 磺胺類藥物
  • Aminoglycosides、其他


  • Achaogen Inc
  • Actelion Ltd.
  • AstaZeneca plc
  • Atox Bio
  • Basilea Pharmaceutica AG
  • Cempra Inc
  • CrystalGenomics, Inc.
  • Cubist Pharmaceuticals, Inc.
  • Destiny Pharma Ltd.
  • Dong Wha Pharmaceuticals
  • Durata Therapeutics, Inc.
  • Eisai
  • Furiex Pharmaceuticals, Inc.
  • GlaxoSmithKline, Plc.
  • Grupo Ferrer Internacional S.A.
  • Insmed Incorporated
  • KaloBios Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals Pte Ltd
  • MicuRx Pharmaceuticals, Inc.
  • Nabriva Therapeutics AG
  • Osel Inc
  • Novartis AG
  • Otonomy, Inc.
  • 大塚製藥
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc
  • Polyphor Ltd.
  • Rebiotix, Inc.
  • Roche Holding AG
  • Savara Pharmaceuticals
  • Sequella, Incorporated
  • Seres Therapeutics, Inc.
  • Summit, plc
  • TaiGen Biotechnology Co., Ltd.
  • Tetraphase Pharmaceuticals, Inc.
  • The Medicines Company
  • Theravance Biopharma Inc



An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don't work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century.

Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs.

The US and world are in the beginning of an emerging crisis of Antibiotic resistance for microbial pathogens. Epidemic antibiotic resistance has been described in numerous pathogens in varying contexts, including, but not limited to: MRSA (methicillin-resistant Staphylococcus aureus), common respiratory pathogens, including Streptococcus pneumoniae and Mycobacterium tuberculosis, and epidemic increases in multidrug-resistant and, increasingly, truly pan-resistant, gram-negative bacilli.

Why is the level of concern increasing now? It is because the increase in organisms resistant to multiple therapies is now coinciding with the reduction in new therapies coming to market to replace ineffective ones.

Herbal medicine, including medicinal plants, was the only way people could treat infectious diseases until the early 20th century. Since then, pharmaceutical drugs have become the main method for treating bacterial infections. However, the pharmaceutical drug pipeline is almost dry. At the same time, growing consumer awareness of the benefits of herbal medicine, along with a backlash against the exorbitant prices and dangerous side effects of pharmaceutical drugs, have led to a renaissance in the use of medicinal plants. Consumers are starting to focus on keeping healthy rather than dealing with acute situations that require the use of expensive pharmaceutical drugs. Medicinal plants fit perfectly into this new paradigm. And for this reason, their use is forecast to grow dramatically.

This report looks at the use of medicinal plants, rather than Antibiotics, to both treat and prevent bacterial infections. Specifically, it provides:

  • A detailed look at Antibiotics and Antimicrobial Resistant drugs.
  • Analysis of the Antibiotics market.
  • In-depth examination of Antibacterial Medicinal Plants.
  • Analysis of the Medicinal Plants market.

Additionally, profiles of 127 private and public companies involved in the Antibiotics and Medicinal Plants industries as producers, distributors, and retailers are given. The report also includes 32 tables and 32 figures.

Table of Contents




  • Report Objectives
  • Methodology and Sources
  • Statistical Notes


  • Bacteria Taxonomy
  • Microbes in Context
  • Antibiotics Definition
  • Quest for Super Drugs
  • Soil Microbes
  • Antibiotic Categories
  • Gram-Positive vs. Gram-Negative Bacteria
  • Static vs. Cidal
  • Susceptibility, Potency and MIC
  • Bactericidal Antibiotics
  • Breakpoint
  • Efficacy and Safety
  • Mechanisms of Action
  • Antibiotic Resistance
  • Resistance Is Nothing New
  • Costs of Antibiotic Resistance
  • Treatment Guidelines
  • Antibiotic Overuse


  • Most Common Infections
  • Antibiotic Resistance Prevention
  • National Action Plan for Combating Antibiotic Resistant Bacteria
  • BARDA and NIAID Budgets
  • Presidential Advisory Council
  • United Kingdom Review on Antimicrobial Resistance
  • Margolis Center for Health Policy
  • GAIN Act
  • 21st Century Cures Act
  • MRSA on the Decline
  • CRE Poses an Urgent Threat
  • Failure Rate High
  • Global Problem
  • U.S. Cases
  • Carbapenems Use Increasing
  • ESBLs Pose a Serious Threat
  • New Delhi Metallo-Beta-Lactamase
  • Clostridium difficile
  • Few New Antibiotics Being Produced
  • Low NPV
  • Cost of Trials
  • New Antibiotics Hard to Discover
  • iChip
  • Five Pharma Companies Left
  • Development Now Done by Startups
  • Numerous Studies on Situation
  • Disaster Planning
  • Path Forward
  • Alternative Is Unimaginable


  • Discovery Platform Has Collapsed
  • New Antibiotic Discovery Process
  • Rationally Improve Existing Antibiotics
  • Rediscover Old Antibiotics
  • Repurpose Old Drugs
  • Discover Untested New Chemical Diversity
  • Community for Open Antimicrobial Drug Discovery
  • Target-Based Approaches
  • Long Time-Lower Success Rates
  • Focus for New Antibiotic Drugs Well Established
  • Dearth of New Antibiotic Drug Classes
  • R&D Development and Commercial Challenges
  • Modest Performance of New Antibiotics
  • Few Big Players Remain
  • New Key Initiatives
  • Growing Wave of Activity in Antibiotics
  • Activity Mostly Led by Biotechs
  • Renewed Enthusiasm
  • Antibiotics in Late Clinical Development
  • Obtaining Investments for New Antibiotics Is Difficult
  • Startups Believe They Can Find New Antibiotics
  • Antibiotics Approved in Recent Years
  • Stewardship
  • New Antibiotics That Have Received Marketing Authorization
  • Disappointing Sales Post-Launch
  • Generic Competition
  • Beta-lactamases, Cephalosporinase and Carbapenemase Inhibitors
  • New Cephalosporins
  • New Aminoglycosides
  • New Pleuromutilins
  • New Tetracyclines
  • New Macrolides
  • New Fluoroquinolones and DNA Gyrase Inhibitors
  • New Oxazolidinones
  • New Fatty Acid Biosynthesis Inhibitors
  • New Folate Biosynthesis Inhibitors
  • Defensin-Mimetic Peptides
  • Other Classes
  • Old Antibiotics with New Dosing
  • Ramoplanin
  • Fusidane
  • Fosfomycin
  • Early-Stage Molecules
  • Analogs of Existing Classes Still Difficult to Develop
  • New Oral Antibiotics for Outpatients Urgently Needed
  • New Oral Antibiotics for Children Urgently Needed
  • Government Incentives Needed
  • Options Market for Antibiotics
  • Antibiotics Prize


  • Antibiotics Production Value
  • Production Value by Class
  • Quinolones
  • Cephalosporins
  • Marcolides
  • Penicillins
  • Carbapenems
  • Tetracyclines
  • Sulfonamides
  • Aminoglycosides
  • Other Antibiotics
  • Production by Region
  • Consumption Volume Data
  • Antibiotic Market Volume
  • Consumption by Country
  • Class Differences by Country
  • Inappropriate Use
  • Public Health Issues
  • Applications
  • Anti-MRSA Antibiotics
  • Cubicin
  • Zyvox
  • Teflaro
  • Tygacil
  • Vibativ
  • Dalvance
  • Other
  • Community Acquired Bacterial Pneumonia
  • Healthcare-Associated Infections Decreasing
  • Medicare Part D
  • Competitive Environment
  • Large Pharma Exits Antibiotics
  • Biotech Enters Antibiotics
  • Antibiotic Deal Making
  • Competitors
  • Market Shares
  • Antibiotic Supply Chains
  • India and China Antibiotic Supply Chains
  • Antibiotic Pollution Issues
  • Chinese Companies
  • North China Pharmaceutical Group
  • CSPC Pharmaceutical Group/Inner Mongolia Changsheng Pharmaceuticals
  • Sinopharm WeiQida
  • Shandong Lukang Pharmaceuticals
  • Harbin Pharmaceutical Group
  • Tonglian Group
  • United Laboratories
  • Indian Companies
  • Aurobindo
  • Mylan Laboratories Ltd.
  • Dr Reddy's
  • Hetero Drugs Ltd.
  • Orchid Pharmaceuticals


  • Achaogen Inc
    (Company Overview, CRE, Plazomicin, Trials, EPIC, CARE, Launch, QIDP Designation, BARDA, Pipeline, C-Scape, LpxC, P. aeruginosa, Antibacterial Monoclonal Antibodies, Other Monoclonal Antibody Programs, Intellectual Property, Competition, Financial)
  • Actelion Ltd.
    (Company Overview)
  • AstaZeneca plc
    (Company Overview, Small Molecule Unit)
  • Atox Bio
    (Company Overview)
  • Basilea Pharmaceutica AG
    (Company Overview, Ceftobiprole)
  • Cempra Inc
    (Company Overview, Solithromycin, Applications, BARDA, Fusidic Acid, ABSSSI)
  • CrystalGenomics, Inc.
    (Company Overview, CG400549)
  • Cubist Pharmaceuticals, Inc.
    (Company Overview, Sivextro)
  • Destiny Pharma Ltd.
    (Company Overview, Pipeline)
  • Dong Wha Pharmaceuticals
    (Company Overview)
  • Durata Therapeutics, Inc.
    (Company Overview)
  • Eisai Co., Ltd.
    (Company Overview)
  • Furiex Pharmaceuticals, Inc.
    (Company Overview)
  • GlaxoSmithKline, Plc.
    (Company Overview, Gepotidacin)
  • Grupo Ferrer Internacional S.A.
    (Company Overview, Ozenoxacin)
  • Insmed Incorporated
    (Company Overview, ARIKAYCE, Approvals, Patent, INS1007)
  • KaloBios Pharmaceuticals, Inc.
    (Company Overview, Technology, KB001-A)
  • Melinta Therapeutics, Inc.
    (Company Overview, Baxdela)
  • Merck & Co., Inc.
    (Company Overview, Cubicin, Primaxin, Zerbaxa, Sivextro, MK-7655A, Acute Care Position)
  • MerLion Pharmaceuticals Pte Ltd
    (Company Overview, Finafloxacin, MRSA, Intraabdominal Infections, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Other Hospital and Critical Care Infections, Helicobacter pylori)
  • MicuRx Pharmaceuticals, Inc.
    (Company Overview)
  • Nabriva Therapeutics AG
    (Company Overview, Lefamulin, BC-7013)
  • Osel Inc
    (Company Overview, LACTIN-V, CBM588)
  • Novartis AG
    (Company Overview, Sandoz, Antibiotics)
  • Otonomy, Inc.
    (Company Overview)
  • Otsuka Pharmaceutical Co. Ltd.
    (Company Overview, Tuberculosis Effects More Than 10 Million, Delamanid, Bedaquiline)
  • Paratek Pharmaceuticals, Inc.
    (Company Overview)
  • Pfizer Inc
    (Company Overview, AstraZeneca Acquisition, Antibiotics, Tygacil)
  • Polyphor Ltd.
    (Company Overview, Technology, Murepavadin, Roche Collaboration)
  • Rebiotix, Inc.
    (Company Overview, RBX2660)
  • Roche Holding AG
    (Company Overview, Antibiotics, OP0595)
  • Savara Pharmaceuticals
    (Company Overview)
  • Sequella, Incorporated
    (Company Overview, Available Markets)
  • Seres Therapeutics, Inc.
    (Company Overview, SER-109)
  • Summit, plc
    (Company Overview)
  • TaiGen Biotechnology Co., Ltd.
    (Company Overview, Taigexyn®)
  • Tetraphase Pharmaceuticals, Inc.
    (Company Overview, Eravacycline, TP-271, TP-6076, QIDP, Licensed from Harvard, BARDA)
  • The Medicines Company
    (Company Overview, Infectious Disease Business, Meropenem-Vaborbactam, MINOCIN®, ORBACTIV®, R&D)
  • Theravance Biopharma Inc
    (Company Overview, VIBATIV, Competition)


  • Aminoglycosides
  • β-Lactams
  • β-Lactam Resistance
  • Penicillins
  • Carbapenems
  • Cephalosporins
  • Fluoroquinolones
  • Lipoglycopeptides
  • Lipopeptides
  • Oxazolidinones
  • Macrolides
  • Tetracyclines


  • Food, Drug, and Cosmetic Act
  • Approval Process
  • Preclinical Studies
  • Clinical Trials
  • Marketing Approval
  • Foreign Clinical Trials
  • Approval Letter
  • Special FDA Expedited Review and Approval Programs
  • Breakthrough Therapy
  • Post-Approval Requirements
  • Section 505(b)(2)
  • Qualified Infectious Disease Product Exclusivity


  • 1.) Microbes Vs. Humans by Factor
  • 2.) Characteristics of Antibiotics by Class
  • 3.) Antibiotics Currently in Clinical Development: March 2017
  • 4.) Global Antibiotics Market ($ Million): 2017-2022
  • 5.) Global Antibiotics Market by Class ($ Million): 2017-2022
  • 6.) Global Antibiotics Production in U.S., EU, Rest of World ($ Million): 2017-2022
  • 7.) MRSA Cases, I.V. MRSA Treatment Days, U.S. Market for Anti-MRSA Antibiotics by Drug and Producer ($ Million): 2017-2022
  • 8.) 10 Most Common Antibiotics Prescribed to Medicare Part D Beneficiaries (Million Claims, $ Million): 2013
  • 9.) 222 Companies Producing or Doing R&D on Antibiotics, Headquarters Country and Website: 2017
  • 10.) Antibiotics Production and Market Shares by Company ($ Million, %): 2016
  • 11.) Achaogen Inc Income Statement ($ Thousand): 2012-2016
  • 12.) AstraZeneca's Small Molecule Antibiotic Products
  • 13.) Merck Revenue by Segment and Products ($ Million): 2016
  • 14) Pfizer Anti-Infective U.S. and Non-U.S. Sales by Product ($ Million): 2013-2020
  • 15.) Classes of Antibiotics by Type and Generic, Brand, Target, MOA, Formulation, AE


  • 1.) Living Organism Taxonomy
  • 2.) Taxonomy of E. coli
  • 3.) Gram Staining and Cell Wall Composition
  • 4.) Bacteriostatic vs. Bactericidal Antibiotics
  • 5.) Time-Dependent vs. Concentration-Dependent Bactericidal Effects
  • 6.) Antibiotic Mechanisms of Action
  • 7.) Publications Citing Antibiotic Resistance (Number): 1987-2015
  • 8.) Antibiotic Mechanisms of Resistance
  • 9.) Costs of the Five Most Common Hospital-Acquired Infections (HAIs) in the U.S. ($ Billion)
  • 10.) Bacterial Infections by Pathogen Species, by CDC Threat Level (Urgent, Serious, Concerning), by Infections/Year (Number), by Drug-Resistant Infections (Number), by Lethal Infections (Number), by MDR Infections (Number), by G+/G-
  • 11.) Percentage of Staphylococcus Aureus Isolates That Are Methicillin Resistant (MRSA) by Country: 2011-2014
  • 12.) Percentage of Carbapenem-Resistant Klebsiella Pneumoniae by Country: 2011-2014
  • 13.) Percentage of Extended-Spectrum Beta-Lactamase Producing Escherichia Coli by Country: 2011-2014
  • 14.) Spread of New Delhi Metallo-Beta-Lactamase-1: First Detection
  • 15.) Different Approaches to Discover New Antibiotics
  • 16.). Examples of Rediscovered Antibiotics
  • 17.) Approved or Late-Stage Clinical Antibiotics That Do Not Obey Drug-Like Rules for Oral Availability
  • 18.) Approved or Late-Stage Clinical Antibiotics with Undesirable Chemical Functional Groups
  • 19.) The CO-ADD Screening Workflow
  • 20.) Target-Based Antibiotics
  • 21.) Typical Antibiotic Drug Development Pathway
  • 22.) Top Antibiotic Resistance Threats Categorized by Level of Concern
  • 23.) New Classes of Antibiotics Discovered by Decade (Number): 1890s-2010s
  • 24.) Generations of Approved Antibiotics
  • 25.) Antibiotic New Molecular Entity Drugs Launched Worldwide (Number): 1980-2015
  • 26.) Past and Forecast Performance of Six Recently Launched Antibiotic Drugs ($ Million): 2014-2022
  • 27.) M&A and Pharma R&D Departure for the Antibiotic Space (Deal Count Number): 1995-2015
  • 28.) Key Antibiotic Initiatives: 2010-2014
  • 29.) U.S. Antibiotic Initiatives and Their Value Chain Targets
  • 30.) European Antibiotic Initiatives and Their Value Chain Targets
  • 31.) Other Antibiotic Initiatives and Their Value Chain Targets
  • 32.) U.S. Venture Capital Raised for Infectious Disease Companies by Novel R&D and Drug Improvement R&D ($ Million, Number of Companies Funded): 2007-2016
  • 33.) Biotech M&A Deals by Therapeutic Area (%): 2013-2015
  • 34.) Developers of Clinical Stage Antibiotics by Type (%): 2016
  • 35.) Venture Capital Antibiotic Startup Investments: 2016
  • 36.) Big Pharma Renewed Interest in Antibiotics: 2016
  • 37.) Product Launches: New Antibiotics vs. Other Brands ($ Million): Two years Post-Launch
  • 38.) Global Antibiotic Consumption by Class (Standard Units): 2000-2010
  • 39.) Antibiotics Consumption Per Person and Growth Rate of Antibiotic Drug Consumption (Standard Units): 2000-2010
  • 40.) Antibiotics Consumption by Class in the U.S., France, Germany, China, India, UK (Standard Units): 2000-2010
  • 41.) Peak Month for Antibiotic Consumption and Correlation Between Consumption and Its 12 Month Harmonic: 2000-2010
  • 42.) U. S. Hospital Discharges for Pneumonia (Number): 1993-2011
  • 43.) Macrolide Market Opportunity: 2017
  • 44.) CABP Antibiotic Retail RXs by Class, Number and Brand: 2016
  • 45.) Small Group Writes a Disproportionate Share of AZ and LEVO CABP Prescriptions
  • 46.) 80,000 Prescribers are Responsible for 60% of TRx Volume
  • 47.) Cumulative Sales of Selected IV Antibiotics Post Launch ($ Million
  • 48.) Global Antibiotic Supply Chain
  • 49.) China and India Antibiotic Supply Chain
  • 50.) Zhuhai United Laboratories, NCPC, Shandong Lukang, CPSC Zhongnuo, Harbin Pharmaceutical Supply Chains
  • 51.) Aurobindo Supply Chain
  • 52.) Orchid Pharmaceuticals and Mylan Supply Chains
  • 53.) Achaogen Product Offering
  • 54.) Plazomicin Trials
  • 55.) Achaogen Products Pipeline
  • 56.) Cempra Portfolio
  • 57.) Solithromycin Range of Indications
  • 58.) Binding of Lefamulin to the PTC
  • 59.) Nabriva Product Candidates and the Status of Development.
  • 60.) Otonomy Product and Product Candidate Pipeline
  • 61.) OTIVIDEX Commercial Opportunity in U.S.
  • 62.) OTIPRIO Commercial Opportunity in U.S.
Back to Top